UK Continues to Face ADHD Medication Shortages

- The national ADHD medication shortage in the UK began in September 2023, initially expected to resolve by December 2023, but has persisted due to a combination of manufacturing issues and a surge in global demand. - A survey revealed the significant impact on patients, with only 8% receiving their medication without interruption. Many patients have been forced to ration their medication, and 44% have expressed concern about potentially losing their jobs due to the shortages. - The supply disruption affects several key medications, including methylphenidate (e.g., Concerta XL, Equasym XL), lisdexamfetamine (Elvanse), guanfacine (Intuniv), and atomoxetine. The availability of specific brands and dosages varies and can change with little notice. - In response to the crisis, the Department of Health and Social Care issued a National Patient Safety Alert and has advised clinicians to temporarily halt prescribing these medications to newly diagnosed patients. - The supply chain remains fragile, with some medications becoming available intermittently. This unpredictability makes it difficult for patients to know if their prescriptions can be filled, leading them to contact multiple pharmacies. - The shortages are not unique to the UK; the United States is also experiencing similar issues with ADHD medication supply. - Healthcare providers have been advised to consider switching patients to alternative medications or different release formulations that may have better availability, though this requires careful clinical supervision. - Due to the shortages, it may not be feasible to provide separate medication supplies for a child's school and home, requiring coordination between parents and schools to share a single supply.